Although the number of patients with adjuvant therapy included in our cohort (n = 15) narrows the interpretation of our results and a larger study is needed, we propose the pS727-STAT3 as a putative biomarker able to indicate treatment after surgery in all advanced-stage ccRCC patients. Here, STAT3 is linked to nonpapillary renal cell carcinoma.